Perindopril: a long-term certainty in treating hypertension.

Area of Science:

• Cardiovascular pharmacology
• Hypertension management

Background:

• The renin-angiotensin-aldosterone system (RAAS) blockade is a cornerstone of antihypertensive therapy.
• Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (AT1-blockers) are key RAAS blockers.
• ACE inhibitors differ from AT1-blockers by affecting bradykinin metabolism, influencing nitric oxide and prostaglandin release for vasodilation.

Purpose of the Study:

• To compare the clinical relevance of different RAAS blockers in hypertensive patients.
• To highlight the specific benefits of ACE inhibitors, particularly perindopril, in improving patient outcomes.

Main Methods:

• Review of morbidity and mortality studies involving RAAS blockers.
• Analysis of the ONTARGET trial comparing ACE inhibitors and AT1-blockers.
• Examination of perindopril's pharmacological profile and clinical evidence.

Main Results:

• ACE inhibitors, especially perindopril, have demonstrated improved overall survival in hypertensive patients.
• The ONTARGET trial showed comparable results between ACE inhibitors and AT1-blockers.
• Perindopril exhibits long-acting, lipophilic properties with high tissue-ACE affinity and a favorable safety profile.

Conclusions:

• Differences in mechanism of action between ACE inhibitors and AT1-blockers may hold clinical significance for hypertension treatment.
• Perindopril is a well-established ACE inhibitor with proven efficacy, safety, and tolerability.
• Fixed-dose combinations involving perindopril can enhance patient compliance and cardiovascular disease treatment effectiveness.